Seeking Alpha
23 Oct 2026, 08:13 UTC · 2h ago
Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case
Impact · against what's priced in
The ITM acquisition and 3Q26 revenue growth are positive developments but largely already reflected in Telix's elevated valuation. The stock's performance now depends more on the successful FDA remediation of ITM-11 than on the deal's announced synergies.
- TLX+0.20
No priced-in read yet
- In context
The $1.65 billion ITM acquisition diversifies isotope supply and is expected to yield $50 million in synergies by FY2027, though a 3.88x forward EV/sales multiple suggests the market is already pricing in significant pipeline success.
Read from the article alone
